Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoglobulin A nephropathy: fish oils and beyond

J Feehally1

  • 1Department of Nephrology, Leicester General Hospital, UK.

Current Opinion in Nephrology and Hypertension
|September 1, 1996
PubMed
Summary

Current IgA nephropathy treatments lack specific efficacy for reducing glomerular IgA deposition. Further research is needed to identify optimal therapies for progressive renal failure and proteinuria.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Executive summary and conclusions from the European Hydration Institute Expert Conference on human hydration, health, and performance.

Nutrition reviews·2015
Same author

A review of the role of exercise and factors affecting its uptake for people with chronic kidney disease (CKD) not requiring renal replacement therapy.

Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki)·2015
Same author

RCPE UK consensus conference statement: Management of acute kidney injury: the role of fluids, e-alerts and biomarkers.

The journal of the Royal College of Physicians of Edinburgh·2013
Same author

Gut permeability in IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2013
Same author

Poorer graft survival in ethnic minorities: results from a multi-centre UK study of kidney transplant outcomes.

Clinical nephrology·2011
Same author

The new Oxford Clinico-Pathological Classification of IgA nephropathy.

Prilozi·2010

Area of Science:

  • Nephrology
  • Immunology

Background:

  • IgA nephropathy (IgAN) lacks targeted treatments to decrease glomerular IgA deposition.
  • Existing trials often focus on patients with proteinuria and progressive renal failure, sharing injury mechanisms with other chronic glomerular diseases.

Purpose of the Study:

  • To review current treatment strategies for IgA nephropathy.
  • To evaluate the efficacy and limitations of existing therapies for IgAN.

Main Methods:

  • Review of controlled trials and existing literature on IgA nephropathy treatments.
  • Analysis of therapeutic options including blood pressure control, ACE inhibitors, fish oil, and immunosuppressive agents.

Main Results:

  • No definitive treatment exists to reduce glomerular IgA deposition in IgAN.
  • Blood pressure control is crucial, but conclusive evidence for angiotensin-converting enzyme (ACE) inhibitors as the primary choice is lacking.
  • Fish oil shows potential benefits, though trial data are inconsistent.
  • Immunosuppressive regimens may offer benefits but carry concerns regarding long-term toxicity.
  • ACE gene polymorphisms could identify high-risk patients for future clinical trials.

Conclusions:

  • Optimal treatment for IgA nephropathy remains elusive, particularly for reducing IgA deposition.
  • Further research, potentially utilizing genetic markers, is necessary to develop effective and safe therapies for IgAN patients with progressive renal failure.

Related Experiment Videos